Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2019-08-09
Target enrollment:
Participant gender:
Summary
RATIONALE: Metformin hydrochloride may make some enzymes active. These enzymes may block
other enzymes needed for cell growth and stop the growth of tumor cells.
PURPOSE: This phase II trial is studying the safety of giving metformin hydrochloride as
first-line therapy in treating patients with locally advanced or metastatic prostate cancer.